Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, double-blind, placebo-controlled, phase IIa study.

This is the first study to evaluate the IL-36 pathway inhibition in AD. Although not statistically significant, numerical improvements were observed in the primary endpoint of change from baseline in EASI score. Spesolimab had an acceptable safety profile, with no unexcepted safety concerns.